AstraZeneca (AZN) Tops Q2 EPS by 17c

Earlier, AstraZeneca (NYSE: AZN) reported Q2 EPS of $1.53, $0.17 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.66 billion versus the consensus estimate of $6.78 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight